Sanofi Makes Strategic Equity Investment in Diabetes Drugmaker Zucara Therapeutics
November 14, 2024
November 14, 2024
BOSTON, Massachusetts, Nov. 14 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Sanofi in connection with Toronto-based Zucara Therapeutics' $20 million Series B financing. Diabetes life sciences company Zucara is developing a once-daily therapeutic, ZT-01, to prevent hypoglycemia in people with diabetes.
Proceeds from the investment will fund the remainder of Zucara's ongoing Phase 2a clinical trial to develop a once-weekly version of . . .
Ropes & Gray advised Sanofi in connection with Toronto-based Zucara Therapeutics' $20 million Series B financing. Diabetes life sciences company Zucara is developing a once-daily therapeutic, ZT-01, to prevent hypoglycemia in people with diabetes.
Proceeds from the investment will fund the remainder of Zucara's ongoing Phase 2a clinical trial to develop a once-weekly version of . . .